The range and lipid-lowering effect of etofibrate as a retard-preparation in patients with hyperlipoproteinemia type IIa
Mertz, D.P.; Loewer, H.; Suermann, I.
Medizinische Klinik 74(51-52): 1953-1956
1979
ISSN/ISBN: 0025-8458 PMID: 542179 Document Number: 146484
Patients with hyperlipoproteinemia, type IIa, were treated with an adequate diet; additionally they were given 500 mg etofibrate daily. Within 14 days the total cholesterol-level in serum, LDL and LDL-cholesterol were reduced significantly, whereas the level of HDL was not affected. The potency of etofibrate is equal to approximately 50 to 80% of the lipid-lowering effect of clofibrate in an optimal dosis of 2 g/day.